

**EKF Diagnostics Holdings plc**  
**("EKF" or the "Company")**

**Notice of results**  
***Investor briefing***

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its interim results for the six months ended 30 June 2020 on Monday 14 September 2020.

**Investor briefing**

EKF Diagnostics will be hosting a live online presentation open to all investors on Monday 14 September at 4.30pm. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and click 'add to meet' EKF Diagnostics via the following link:

<https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor>

For those investors who have already registered and added to meet the Company, they will automatically be invited.

Questions can be submitted pre-event via the Investor Meet Company dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will aim to address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

**EKF Diagnostics Holdings plc**  
Christopher Mills, Non-executive Chairman  
Julian Baines, CEO  
Richard Evans, FD & COO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
**Tel: +44 (0) 29 2071 0570**

**N+1 Singer**  
Aubrey Powell / George Tzimas (Corporate Finance)  
Tom Salvesen (Corporate Broking)

**Tel: 020 7496 3000**

**Walbrook PR Limited**  
Paul McManus / Lianne Cawthorne

**Tel: +44 (0) 20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)**  
Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303

**About EKF Diagnostics Holdings plc**

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORKZGMLGGGGZM admin Notice of Results 31159656 A Thu, 09/10/2020 - 12:00 LSE RNS  
Advance Notice of Results EKF